289 related articles for article (PubMed ID: 31903139)
1.
Osinski V; Bauknight DK; Dasa SSK; Harms MJ; Kroon T; Marshall MA; Garmey JC; Nguyen AT; Hartman J; Upadhye A; Srikakulapu P; Zhou A; O'Mahony G; Klibanov AL; Kelly KA; Boucher J; McNamara CA
Theranostics; 2020; 10(2):585-601. PubMed ID: 31903139
[TBL] [Abstract][Full Text] [Related]
2. Importance of thorough tissue and cellular level characterization of targeted drugs in the evaluation of pharmacodynamic effects.
Bauknight DK; Osinski V; Dasa SSK; Nguyen AT; Marshall MA; Hartman J; Harms M; O'Mahony G; Boucher J; Klibanov AL; McNamara CA; Kelly KA
PLoS One; 2019; 14(11):e0224917. PubMed ID: 31725756
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
Cha DR; Zhang X; Zhang Y; Wu J; Su D; Han JY; Fang X; Yu B; Breyer MD; Guan Y
Diabetes; 2007 Aug; 56(8):2036-45. PubMed ID: 17536062
[TBL] [Abstract][Full Text] [Related]
4. NPY
Wittrisch S; Klöting N; Mörl K; Chakaroun R; Blüher M; Beck-Sickinger AG
Mol Metab; 2020 Jan; 31():163-180. PubMed ID: 31918918
[TBL] [Abstract][Full Text] [Related]
5. Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice.
Zadelaar AS; Boesten LS; Jukema JW; van Vlijmen BJ; Kooistra T; Emeis JJ; Lundholm E; Camejo G; Havekes LM
Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2560-6. PubMed ID: 16931788
[TBL] [Abstract][Full Text] [Related]
6. The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice.
van der Hoorn JW; Jukema JW; Havekes LM; Lundholm E; Camejo G; Rensen PC; Princen HM
Br J Pharmacol; 2009 Apr; 156(7):1067-75. PubMed ID: 19220285
[TBL] [Abstract][Full Text] [Related]
7. [Peroxisome proliferator-activated receptor α/γ agonist tesaglitazar stabilizes atherosclerotic plaque in diabetic low density lipoprotein receptor knockout mice].
Zhang BC; Li XK; Che WL; Li WM; Hou L; Wei YD; Xu YW
Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Feb; 41(2):143-9. PubMed ID: 23710746
[TBL] [Abstract][Full Text] [Related]
8. PPAR Agonists: I. Role of Receptor Subunits in Alcohol Consumption in Male and Female Mice.
Blednov YA; Black M; Benavidez JM; Stamatakis EE; Harris RA
Alcohol Clin Exp Res; 2016 Mar; 40(3):553-62. PubMed ID: 26857685
[TBL] [Abstract][Full Text] [Related]
9. Proliferative and molecular effects of the dual PPARalpha/gamma agonist tesaglitazar in rat adipose tissues: relevance for induction of fibrosarcoma.
Glinghammar B; Berg AL; Bjurström S; Stockling K; Blomgren B; Westerberg R; Skånberg I; Hellmold H; Andersson U
Toxicol Pathol; 2011 Feb; 39(2):325-36. PubMed ID: 21270424
[TBL] [Abstract][Full Text] [Related]
10. Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats.
Oakes ND; Thalén P; Hultstrand T; Jacinto S; Camejo G; Wallin B; Ljung B
Am J Physiol Regul Integr Comp Physiol; 2005 Oct; 289(4):R938-46. PubMed ID: 16183630
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo--a study using the novel PPARalpha/gamma agonist tesaglitazar.
Hegarty BD; Furler SM; Oakes ND; Kraegen EW; Cooney GJ
Endocrinology; 2004 Jul; 145(7):3158-64. PubMed ID: 15059948
[TBL] [Abstract][Full Text] [Related]
12. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice.
Chira EC; McMillen TS; Wang S; Haw A; O'Brien KD; Wight TN; Chait A
Atherosclerosis; 2007 Nov; 195(1):100-9. PubMed ID: 17214992
[TBL] [Abstract][Full Text] [Related]
13. Tesaglitazar, a dual peroxisome proliferator-activated receptor agonist (PPAR alpha/gamma), improves metabolic abnormalities and reduces renal injury in obese Zucker rats.
Liao J; Soltani Z; Ebenezer P; Isidro-Carrión AA; Zhang R; Asghar A; Aguilar E; Francis J; Hu X; Ferder L; Reisin E
Nephron Exp Nephrol; 2010; 114(2):e61-8. PubMed ID: 19887847
[TBL] [Abstract][Full Text] [Related]
14. Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats.
Hellmold H; Zhang H; Andersson U; Blomgren B; Holland T; Berg AL; Elebring M; Sjögren N; Bamberg K; Dahl B; Westerberg R; Dillner B; Tugwood J; Tugwood J; Roberts R; Lundholm E; Camejo G; Skånberg I; Evans J
Toxicol Sci; 2007 Jul; 98(1):63-74. PubMed ID: 17468185
[TBL] [Abstract][Full Text] [Related]
15. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
[TBL] [Abstract][Full Text] [Related]
16. Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPARalpha/gamma agonist, tesaglitazar.
Fagerberg B; Schuster H; Birketvedt GS; Tonstad S; Ohman KP; Gause-Nilsson I;
Diab Vasc Dis Res; 2007 Sep; 4(3):174-80. PubMed ID: 17907107
[TBL] [Abstract][Full Text] [Related]
17. Tesaglitazar, a dual PPAR-α/γ agonist, hamster carcinogenicity, investigative animal and clinical studies.
Lindblom P; Berg AL; Zhang H; Westerberg R; Tugwood J; Lundgren H; Marcusson-Ståhl M; Sjögren N; Blomgren B; Öhman P; Skånberg I; Evans J; Hellmold H
Toxicol Pathol; 2012; 40(1):18-32. PubMed ID: 22131108
[TBL] [Abstract][Full Text] [Related]
18. Tesaglitazar.
Kamber N; Davis TM
IDrugs; 2005 Nov; 8(11):927-35. PubMed ID: 16254788
[TBL] [Abstract][Full Text] [Related]
19. Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in rat hepatocytes.
Rogue A; Renaud MP; Claude N; Guillouzo A; Spire C
Toxicol Appl Pharmacol; 2011 Jul; 254(1):18-31. PubMed ID: 21515302
[TBL] [Abstract][Full Text] [Related]
20. Dual peroxisome-proliferator-activated-receptor-α/γ activation inhibits SIRT1-PGC1α axis and causes cardiac dysfunction.
Kalliora C; Kyriazis ID; Oka SI; Lieu MJ; Yue Y; Area-Gomez E; Pol CJ; Tian Y; Mizushima W; Chin A; Scerbo D; Schulze PC; Civelek M; Sadoshima J; Madesh M; Goldberg IJ; Drosatos K
JCI Insight; 2019 Aug; 5(17):. PubMed ID: 31393858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
